Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02498587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Short Period Incidence Study of Severe Acute Respiratory Illness

Study acronym: SPRINT-SARI
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Enrollment target: 1000 to 15000
    • Primary completion date: Nov 2024 to Dec 2026
    • Study completion date: Dec 2024 to Dec 2026
    • Site contact updated
    v5
  2. Notable Primary completion date: Oct 2020 to Nov 2024
    • Study completion date: Dec 2022 to Dec 2024
    v4
  3. Minor Site contact updatedv3
  4. Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: Oct 2017 to Oct 2020
    • Start date: Nov 2015 to Jan 2016
    • Study completion date: Dec 2020 to Dec 2022
    • Site details revised
    • Eligibility criteria expanded, about 1 word
  5. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-centre, prospective, short period incidence observational study of patients in participating hospitals and intensive care units (ICUs) with SARI. The study period will occur, in both Northern and Southern hemispheric winters. The study period will comprise a 5 to 7-day cohort study in which patients meeting a SARI case-definition, who are newly admitted to the hospitals / ICUs at participating sites, will be included in the study. The study will be conducted in 20 to 40-hospital/ ICU-based research networks globally. All clinical information and sample data will only be recorded if taken as part of the routine clinical practice at each site and only fully anonymised and de-identified data will be submitted centrally. The primary aim of this study is to establishing a research response capability for a future epidemic / pandemic through a global SARI observational study. The secondary aim of this study is to investigate the descriptive epidemiology and microbiology profiles of patients with SARI. The tertiary aim of this study is to assess the Ethics, Administrative, Regulatory and Logistic (EARL) barriers to conducting pandemic research on a global level.
Trial Details
NCT Number NCT02498587
Lead Sponsor Australian and New Zealand Intensive Care Research Centre
Collaborators: International Severe Acute Respiratory and Emerging Infection Consortium, The International Forum of Acute Care Trialists
Conditions
(from sponsor)
Severe Acute Respiratory Infection
Enrollment 15,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov